1. Home
  2. AVLN vs UFCS Comparison

AVLN vs UFCS Comparison

Compare AVLN & UFCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

N/A

Current Price

$29.89

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Logo United Fire Group Inc.

UFCS

United Fire Group Inc.

N/A

Current Price

$51.10

Market Cap

1.4B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
AVLN
UFCS
Founded
2011
1946
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.4B
IPO Year
2026
1995

Fundamental Metrics

Financial Performance
Metric
AVLN
UFCS
Price
$29.89
$51.10
Analyst Decision
Strong Buy
Buy
Analyst Count
5
2
Target Price
★ $61.80
$57.50
AVG Volume (30 Days)
★ 432.2K
124.8K
Earning Date
11-12-2026
11-03-2026
Dividend Yield
N/A
★ 1.56%
EPS Growth
N/A
★ 87.45
EPS
N/A
★ 3.78
Revenue
N/A
★ $1,386,412,000.00
Revenue This Year
N/A
$15.24
Revenue Next Year
N/A
$19.13
P/E Ratio
★ N/A
$13.62
Revenue Growth
N/A
★ 10.62
52 Week Low
$22.24
$33.53
52 Week High
$40.17
$58.20

Technical Indicators

Market Signals
Indicator
AVLN
UFCS
Relative Strength Index (RSI) 58.89 40.82
Support Level $25.86 $47.79
Resistance Level $33.32 $55.12
Average True Range (ATR) 1.93 2.25
MACD 0.67 -0.43
Stochastic Oscillator 74.04 39.52

Price Performance

Historical Comparison
AVLN
UFCS

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

About UFCS United Fire Group Inc.

United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.

Share on Social Networks: